Association of bacterial genotypes and epidemiological features with treatment failure in hemodialysis patients with methicillin-resistant *Staphylococcus aureus* bacteremia

Shang-Yi Lin\(^\text{1,2}\), Hung-Pin Tu\(^\text{3}\), Tun-Chieh Chen\(^\text{1,4}\), Mei-Chiou Shen\(^\text{5}\), Yi-Wen Chiu\(^\text{6}\), Yen-Hsu Chen\(^\text{1,2}\), Po-Liang Lu\(^\text{1,2,7\,*}\)

1 Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 2 School of Medicine, Graduate Institute of Medicine, College of Medicine, Sepsis Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan, 3 Department of Public Health and Environmental Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 4 Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 5 Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 6 Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 7 Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

* d830166@gmail.com

Abstract

**Objectives**

Methicillin-resistant *Staphylococcus aureus* (MRSA) infections in the hemodialysis (HD) population are epidemiologically classified as healthcare-associated infections. The data about the clinical impact and bacterial characteristics of hospital-onset (HO)- and community-onset (CO)-MRSA in HD patients are scarce. The current study analyzed the difference in the clinical and molecular characteristics of HO-MRSA and CO-MRSA.

**Methods**

We performed a retrospective review and molecular analysis of clinical isolates from 106 HD patients with MRSA bacteremia from 2009 to 2014. CA genotypes were defined as isolates carrying the SCC\(^\text{mec}\) type IV or V, and HA genotypes were defined as isolates harboring SCC\(^\text{mec}\) type I, II, or III.

**Results**

CO-MRSA infections occurred in 76 patients, and 30 patients had HO-MRSA infections. There was no significant difference in the treatment failure rates between patients with CO-MRSA infections and those with HO-MRSA infections. CA genotypes were associated with less treatment failure (odds ratio [OR]: 0.18; 95% confidence interval [95% CI], 0.07–0.49; \(p = 0.001\)). For isolates with a vancomycin minimum inhibitory concentration (MIC) < 1.5
mg/L, the multivariate analysis revealed that HA genotypes and cuffed tunneled catheter use were associated with treatment failure. For isolates with a vancomycin MIC ≥ 1.5 mg/L, the only risk factor for treatment failure was a higher Pitt score (OR: 1.76; 95% CI, 1.02–3.05; \( p = 0.043 \)).

**Conclusion**

CA genotypes, but not the epidemiologic classification of CO-MRSA, impacted the clinical outcome of MRSA bacteremia in the HD population.

**Introduction**

Although there has been a decreasing trend in the incidence of methicillin-resistant *Staphylococcus aureus* (MRSA) infections in the past decade [1], MRSA remains a major threat to patients all over the world. The hemodialysis (HD) population has a high risk for invasive MRSA infections that is more than 100-fold higher than the incidence rate of the general population (45.2/1000 vs. 0.2–0.4/1000) [2]. The incidence of invasive MRSA infections among dialysis patients decreased by 7.3% annually during 2005–2011 in the USA [3]. However, a rate of 19.9% for healthcare-associated invasive MRSA infections was identified among dialysis patients in the USA in 2014 [4]. MRSA infections in HD patients are associated with long hospitalizations, high costs and mortality [5]. Therefore, the impact of MRSA infections in the HD population remains significant.

All MRSA infections in the HD population are classified as healthcare-associated (HA) infection according to epidemiologic classification. HA-MRSA infection can be further classified as healthcare-associated hospital-onset (HO) or healthcare-associated community-onset (CO) infections based on infection development in the hospital or community [4]. According to molecular classification, MRSA strains are classified as HA- or community-associated (CA)-MRSA strains by genotyping. Strains carrying SCC\textit{mec} element type I, II or III are defined as HA genotypes, and those harboring SCC\textit{mec} type IV or V are defined as CA genotypes [6, 7]. The high prevalence and disease burden of CA-MRSA have been increasingly observed in many countries [8 – 10]. Furthermore, CA genotypes are increasingly implicated in nosocomial infections and may eventually displace HA genotypes in hospitals to become the predominant nosocomial MRSA isolates [11]. A population-based study in the USA showed the proportion of CA genotypes increased among chronic dialysis patients [3]. However, very little is known regarding whether these differences are associated with the clinical outcomes of MRSA bacteremia among the HD population [3]. We aimed to investigate the epidemiologic differences, clinical presentations, molecular characteristics and outcomes in HD patients with MRSA bacteremia in this study.

**Materials and methods**

**Study design and patient population**

This retrospective study was conducted in Kaohsiung Medical University Hospital, a 1600-bed medical center in Taiwan, after approval was received from the institutional review board (IRB No. KMUH-IRB-990139). The medical records of HD patients with MRSA bacteremia from January 2009 to October 2014 were reviewed. Subjects were included in the analysis if they were at least 20 years old, required HD and had blood cultures yielding MRSA isolates.
Data collection and case definitions

We collected data on patient demographics, clinical characteristics, co-morbidities, the Charlson co-morbidity index, healthcare-associated (HA) risk factors in the 12 months preceding the MRSA-positive culture, disease severity, length of hospitalization, infection foci, empiric and definitive therapies, vancomycin trough level (if available), laboratory drug susceptibility results and outcomes.

The HA risk factors for MRSA infections are defined as follows: (1) prior hospitalization, (2) indwelling percutaneous devices or catheters at the present admission, (3) receiving surgery, (4) long-term care facility or nursing home residence, and (5) MRSA colonization or infection within one year before bacteremia onset [12]. The severity of bacteremia was graded as follows: no sepsis or simple sepsis, severe sepsis, and septic shock [13]. Thrombocytopenia was defined as a platelet count <100,000 platelets/mm$^3$, as determined by a complete blood cell count. The severity of sepsis at initial presentation was assessed by the Pitt score. The empirical antibiotic was defined as the antibiotic administered within the first 48 h of index blood culture collection. Antibiotic therapies were considered effective if the isolate was susceptible to at least one of the antibiotics administered according to the 2010 CLSI guidelines [14]. The vancomycin trough level was measured after at least 2 doses of vancomycin [15], and inadequate vancomycin therapy was defined as a vancomycin trough level of <15 mg/L [16]. The concomitant use of β-lactam was defined as β-lactams administration for ≥24 h concurrent with intravenous vancomycin [17].

The primary outcome was treatment failure, which was defined in terms of the following events: (1) 30-day mortality; (2) persistent bacteremia, defined as a positive blood culture for MRSA obtained after >7 days of effective antibiotic therapy; or (3) recurrent MRSA bacteremia within 30 days of discontinuation of anti-MRSA therapy.

Classification of MRSA bloodstream infections

Patients with at least one positive MRSA blood culture were included in the study. Data collection and genotyping were conducted only on the first blood isolate from the same patient. Cases were identified as HO by the CDC epidemiologic definitions if the culture-positive sample was obtained >48 h after admission and as CO if the culture-positive sample was obtained ≤48 h after admission [3, 4]. Strains carrying SCCmec element type I, II or III are defined as HA genotypes, and those harboring SCCmec type IV or V are defined as CA genotypes [6, 7]. The MRSA isolates were classified into two subgroups according to vancomycin minimal inhibitory concentrations (MICs): low (<1.5 mg/L) or high (≥1.5 mg/L).

Microbiological and molecular characteristics of MRSA isolates

MRSA isolates were collected from the microbiology laboratory of Kaohsiung Medical University Hospital at the time of blood culture identification and stored at -80°C. All S. aureus isolates were identified and tested for susceptibility to antimicrobial agents using the Vitek 2 system (bioMérieux, Marcyl'Etoile, France). The interpretation of susceptibility followed Clinical and Laboratory Standards Institute (CLSI) guidelines [14]. Vancomycin MICs were determined by the Vancomycin E-test (AB Biodisk, Solna, Sweden) using a 0.5 McFarland inoculum streaked evenly with a swab onto Mueller-Hinton agar plates [18].

A multiplex polymerase chain reaction (PCR) method was used for SCCmec typing, and multilocus sequence typing (MLST) was performed as described in previous studies [19, 20]. MLST and SCCmec types were further inferred for all strains. The PCR method described by Gilot P. et al. was used to determine accessory gene regulator (agr) typing [21].
Statistical analysis

Categorical variables were compared by a chi-square test or Fisher’s exact test. Continuous variables were compared by Student’s t-test or the Mann-Whitney U-test, as appropriate. The proportions of CO-MRSA and CA genotypes over 6 years were examined using the linear regression model for linear trends. Variables with a p-value less than 0.05 in the univariate analysis were incorporated into a multivariate analysis. Of the many parameters that represent the initial clinical severity of illness, only the Pitt score was included in the multivariate analysis to avoid multicolinearity. A multivariate backward logistic regression was performed to evaluate the independent effects on the primary outcome after adjustments for baseline discrepancies between groups. A p-value less than 0.05 was considered significant. The analyses were performed using SPSS v19 (SPSS Inc., Chicago, IL, USA).

Results

Clinical characteristics of the CO- and HO-MRSA groups

A total of 106 patients with MRSA bacteremia were identified during the study period. CO-MRSA infections occurred in 76 patients (71.7%), and 30 patients (28.3%) had HO-MRSA infections. The clinical characteristics of CO- and HO-MRSA infections are shown in Table 1. Age, weight, and the percentages of co-morbidities were similar in both groups. A significantly higher percentage of patients with HO-MRSA infections had received a shorter duration of HD at the time of bacteremia. Most of the underlying diseases among both groups were similar, but a significantly higher percentage of patients with CO-MRSA bacteremia had indwelling percutaneous devices or catheters at admission. Most catheters were non-cuffed tunneled catheters. The initial presentation in patients with HO-MRSA bacteremia was more severe (higher percentages of severe sepsis/shock, ICU admission, Pitt score) than in patients with CO-MRSA bacteremia. The majority of infection foci in both groups were catheter-related infections, arteriovenous fistula/graft infections and skin and soft tissue infections. No significant difference was observed with regard to antimicrobial treatment, including the percentage of effective empiric, definitive antibiotics and concomitant therapies, between the groups. Catheter removal was performed in 39 of 51 (76.5%) patients with catheter-related infection. Arteriovenous fistulas or grafts were removed in 16 of 23 (69.6%) patients with an arteriovenous fistula/graft infection. The rates of catheter and arteriovenous fistula or graft removal were similar in both groups (S1 Table). No significant difference was observed with regard to the rate of source removal and time to remove an infected device for most infection foci between CO- and HO-MRSA groups, except for skin and soft tissue infection (S1 Table). However, there was no significant difference in treatment failure rates between the two groups.

Molecular characteristics of the CO- and HO-MRSA groups

SCCmec genotyping and MRSA MLST typing were available for 96 MRSA isolates (90.6% of cases). Among the 96 isolates, thirty-eight (39.6%) isolates were SCCmec type III, twenty-five (26.0%) were SCCmec type V, twenty-three (24.0%) were SCCmec type IV, six (6.3%) were SCCmec type II, one (1.0%) was SCCmec type I and three (3.1%) isolates were untypable. The molecular characteristics of CO- and HO-MRSA isolates are presented in Table 1. Significantly different proportions of SCCmec genotypes were observed between HO- and CO-MRSA isolates. Most HAHO-MRSA isolates were HA-genotypes (76.0%), and most HACO-MRSA isolates were CA-genotypes (61.8%).
Table 1. Demographic data, clinical features, molecular characteristics and therapeutic characteristics between healthcare-associated community onset (CO)- and healthcare-associated hospital onset (HO)- methicillin-resistant *Staphylococcus aureus* (MRSA) infections in hemodialysis patients.

|                         | CO-MRSA (n = 76) | HO-MRSA (n = 30) | \( P \) value |
|-------------------------|------------------|-----------------|--------------|
| Male                    | 36 (47.4)        | 15 (50.0)       | 0.807        |
| Age, mean ± SD          | 67.93 ± 12.71    | 68.57 ± 13.27   | 0.820        |
| Weight (kg)             | 55.30 ± 10.61    | 52.68 ± 10.98   | 0.265        |
| \( <1 \) year           | 31 (40.8)        | 24 (80.0)       | 0.000        |
| \( \geq 1 \) year       | 45 (60.2)        | 6 (20.0)        |              |
| Types of vascular access\( ^a \) |                   |                 |              |
| NCTC                    | 28 (36.8)        | 17 (56.7)       | 0.063        |
| AVG                     | 16 (21.1)        | 2 (6.7)         | 0.090        |
| AVF                     | 15 (19.7)        | 8 (26.7)        | 0.436        |
| CTC                     | 17 (22.4)        | 2 (6.7)         | 0.089        |
| Medical history         |                   |                 |              |
| Diabetes                | 47 (61.8)        | 22 (73.3)       | 0.264        |
| Congestive heart failure| 18 (23.7)        | 7 (23.3)        | 0.969        |
| Hypertension            | 47 (61.8)        | 16 (53.3)       | 0.422        |
| Cardiovascular disease  | 23 (30.3)        | 10 (33.3)       | 0.758        |
| Cancer                  | 10 (13.2)        | 7 (23.3)        | 0.198        |
| Charlson comorbidity score | 4.97±1.86       | 5.57±1.59       | 0.128        |
| HA risk factors         |                   |                 |              |
| Hospitalization         | 65 (85.5)        | 27 (90.0)       | 0.753        |
| Use of percutaneous devices or catheters | 39 (51.3) | 22 (73.3) | 0.039 |
| Surgery                 | 40 (52.6)        | 11 (36.7)       | 0.138        |
| Long-term-care facility residence | 29 (38.2) | 11 (36.7) | 0.887 |
| Previous MRSA colonization/infection | 11 (14.5) | 6 (20.0) | 0.485 |
| Median vancomycin MIC (mg/liter \( \text{IQR} \)) \( \geq 1.5 \) | 1.0(0.75–1.5) | 1.5 (1.0–1.5) | 0.055 |
| SCCmec types\( ^b \)   |                   |                 | 0.001        |
| I, II or III            | 26 (38.2)        | 19 (66.7)       |              |
| IV, V                   | 42 (61.8)        | 6 (24.0)        |              |
| Major MLST types (%)    | ST59 (17.1)      | ST239 (33.3)    | 0.157        |
| Major agr type (%)      | Type 1 (75%)     | Type 1 (91.3%)  | 0.202        |
| Initial presentation    |                   |                 |              |
| Thrombocytopenia        | 17 (22.4)        | 12 (40.0)       | 0.067        |
| Severe sepsis/shock     | 20 (26.3)        | 13 (43.3)       | 0.088        |
| Pitt score, mean ± SD   | 2.25 ± 1.39      | 3.20 ± 1.79     | 0.004        |
| ICU admission           | 19 (25.0)        | 20 (66.7)       | 0.000        |
| Infection foci          |                   |                 |              |
| Skin and soft tissue    | 8 (10.5)         | 3 (10.0)        | 1.000        |
| Catheter-related infection | 29 (38.2)   | 22 (73.3)       | 0.001        |
| Arteriovenous fistula/graft infection | 21 (27.6) | 2 (6.7) | 0.019 |
| Endocarditis            | 8 (10.5)         | 1(3.3)          | 0.440        |
| Orthopedic infection    | 5 (6.6)          | 0 (0)           | 0.318        |
| Other/unknown infection sites | 5 (6.6) | 2 (6.7) | 1.000 |
| Effective empiric antibiotics\( ^d \) | 46 (60.5) | 15 (50) | 0.323 |
| Definitive effective antibiotics | 73 (96.1) | 28 (93.3) | 0.712 |

(Continued)
Table 1. (Continued)

|                         | CO-MRSA (n = 76) | HO-MRSA (n = 30) | P value |
|-------------------------|------------------|------------------|---------|
| Vancomycin              | 65 (85.5)        | 26 (86.7)        |         |
| Other anti-MRSA agents  | 8 (10.5)         | 2 (6.7)          |         |
| Mean vancomycin trough<sup>a</sup> | 16.37 ± 5.93    | 13.26 ± 4.83     | 0.067   |
| Inadequate vancomycin therapy<sup>b</sup> | 14 (33.3)       | 9 (56.3)         | 0.111   |
| Concomitant use of β-lactam antibiotics<sup>c</sup> | 34 (44.7)       | 18 (60.0)        | 0.157   |
| Time to remove infected source, days<sup>d</sup> | 4.94 ± 6.57     | 4.76 ± 4.47      | 0.912   |

**Outcome**

|                         |                 |                 |         |
|-------------------------|-----------------|-----------------|---------|
| Treatment failure       | 32 (42.1)       | 17 (56.7)       | 0.176   |
| Persistent bacteremia   | 13 (17.1)       | 5 (16.7)        | 1.000   |
| 30-days mortality       | 18 (23.7)       | 13 (43.3)       | **0.045**|
| Recurrent bacteremia    | 19 (25.0)       | 6 (20.0)        | 0.585   |

AVF, arteriovenous fistula; AVG, arteriovenous graft; CTC, cuffed tunneled catheter; HA, healthcare-associated; MRSA, methicillin-resistant *Staphylococcus aureus*; NCTC, non-cuffed tunneled catheter; SD, standard deviation; TC, tunneled catheter

<sup>a</sup> one instance of missing data in the HO-MRSA group

<sup>b</sup> data for 96 (90.6%) isolates were available for SCC<sub>mec</sub> typing, 3 isolates were untypeable

<sup>c</sup> data for 96 (90.6%) isolates were available for agr typing, 13 isolates were untypeable.

<sup>d</sup> defined as the intravenous administration of vancomycin, teicoplanin, daptomycin, or linezolid within 48 h of obtaining the index blood culture

<sup>e</sup> vancomycin trough levels were tested in 58 patients, 42 in the CO-MRSA group and 16 in the HO-MRSA group.

<sup>f</sup> defined as a vancomycin trough level of < 15 mg/L measured after the 3rd dialysis program.

<sup>g</sup> β-lactam antibiotics, including ampicillin/sulbactam, piperacillin/tazobactam, ceftriaxone, ceftazidime, cefepime, ertapenem, imipenem, and meropenem

<sup>h</sup> first positive blood culture for MRSA as the index date

https://doi.org/10.1371/journal.pone.0198486.t001

The proportions of HO- and CO-MRSA infections for each year of the study are presented in Fig 1A. The differences in SCC<sub>mec</sub> types by year are shown in Fig 1B. The proportion of CO-MRSA increased over time (p = 0.062). The proportion of CA genotypes significantly increased with time (p = 0.018).

![Fig 1](https://doi.org/10.1371/journal.pone.0198486.g001)

https://doi.org/10.1371/journal.pone.0198486.g001
ST239 was the most common MLST type. It accounted for 23 (23.9%) isolates. ST59 accounted for 17 (17.7%) isolates, and ST45 accounted for 13 (13.5%) isolates. The remaining isolates belonged to various other ST types. ST239 was identified in 33.3% of HO-MRSA cases and in 17.1% of CO-MRSA cases. ST45 and ST59 were identified in 20.0% of HO-MRSA cases and in 31.5% of CO-MRSA cases. The genotype analysis of the \(\textit{agr}\) gene revealed that most isolates belonged to \(\textit{agr}\) type 1 (Table 1).

### Outcome associations with the SCC\(\text{mec}\) genotypes

The main clinical characteristics of the MRSA bacteremia cases infected with HA and CA genotypes were not significantly different (S2 Table). The numbers of HA risk factors were not significantly different for cases of both groups (\(p = 0.243\)). Compared with cases with CA genotypes, cases with HA genotypes showed more severe manifestations relative to the proportions of severe sepsis/shock and higher Pitt scores. There was no significant difference in antimicrobial treatment administration for cases of both groups, including the percentage of effective empiric, definitive antibiotics and concomitant therapies. No significant difference was observed with regard to the rate of source removal and time to remove infected devices between CA and HA genotypes (S3 Table).

SCC\(\text{mec}\) type III MRSA isolates had the highest ratio of high vancomycin MIC (2 mg/L) (9/38, 23.7%), followed by SCC\(\text{mec}\) type II (1/6, 16.7%), SCC\(\text{mec}\) type V (1/25, 4%) and 0% in SCC\(\text{mec}\) type IV isolates. The main MLST type of MRSA with SCC\(\text{mec}\) type III isolates was ST239, the main MLST type with SCC\(\text{mec}\) type IV was ST59, and the main MLST type with SCC\(\text{mec}\) type V was ST45.

Treatment failure was significantly lower in patients with CA genotypes of MRSA bacteremia in the univariate analysis (OR, 0.15; 95% CI, 0.06–0.37; \(p < 0.001\)). This association was driven by differences between treatment groups with regard to 30-day mortality (OR, 0.20; 95% CI, 0.07–0.53; \(p = 0.001\)), persistent bacteremia (OR, 0.28; 95% CI, 0.08–0.96; \(p = 0.048\)) and recurrent bacteremia (OR, 0.29; 95% CI, 0.10–0.82; \(p = 0.016\)) (Fig 2).

### Predictors of treatment failure

In the study, 49 (46.2%) cases had treatment failure outcomes. There was no significant difference in the primary outcome between patients with HO-MRSA infections versus CO-MRSA infections (OR, 1.80; 95% CI, 0.77–4.22; \(p = 0.176\)). In the univariate analysis, cuffed tunneled catheter use, underlying cardiovascular diseases, a history of MRSA colonization or infection, initially severe clinical presentation, infective endocarditis, high vancomycin MICs and SCC\(\text{mec}\) type were associated with treatment failure (Table 2). The multivariate analysis revealed that a higher Pitt score was associated with treatment failure (OR:1.81; 95% CI, 1.23–2.67; \(p = 0.003\)) and CA genotypes (OR: 0.18; 95% CI, 0.07–0.49; \(p = 0.001\)) were associated with better primary outcomes (Table 3).

We further explored whether the vancomycin MIC level differences between different SCC\(\text{mec}\) type MRSA isolates accounted for the disparity in clinical impacts on MRSA bacteremia patients. A subgroup analysis stratified by vancomycin MIC was conducted to clarify this possible confounding effect. In the group with a vancomycin MIC < 1.5 mg/L (\(n = 57\)), the multivariate analysis showed that cuffed tunneled catheter use was associated with treatment failure (OR:8.09; 95% CI, 1.32–49.73; \(p = 0.024\)) and that CA genotypes (OR: 0.03; 95% CI, 0.003–0.26; \(p = 0.001\)) were associated with better primary outcomes. In the group with a vancomycin MIC \(\geq 1.5\) mg/L (\(n = 47\)), the only risk factor for treatment failure was Pitt score (OR: 1.76; 95% CI, 1.02–3.05; \(p = 0.043\)) (Table 3). The association between CA genotypes and
treatment failure was consistently seen in subgroup analyses, except for patients with Pitt score ≥2 (OR: 0.20; 95% CI, 0.03–1.19; p = 0.076) (Table 4).

Discussion

In this study, we identified an increasing trend of CO-MRSA in the HD population with MRSA bacteremia in a Taiwanese medical center during 2009–2014. Increasingly, MRSA bacteremia cases in the HD population in Taiwan are due to CA-genotypes, indicating the successful spread of CA genotypes in the HD population. This finding that CA- and HA-MRSA strains infected HD patients in healthcare facilities is similar to the situation of the co-existence of CA and HA genotypes in hospital settings [1, 22, 23]. Our results revealed that the CA genotype is a better predictor of clinical outcome than the epidemiologic classification of CO- or HO-infections. This strain-specific virulence factor effect was an independent risk factor for treatment outcomes in a subgroup analysis for patients with a vancomycin MIC < 1.5 mg/L, but this effect was attenuated with a vancomycin MIC ≥1.5 mg/L.

In Taiwan, ST59 is the major CA MLST type, and ST239 and ST45 are the most common MLST types for hospital-acquired infections and healthcare-associated infections, respectively [24, 25]. Our results revealed the existence of these three major MLST types in the HD population. We found increasing infections from CA genotypes in the HD population in Taiwan, a trend that matches the increase in CA genotypes observed in the HD population in USA [3]. It has been reported in the USA and in Taiwan that CA genotypes were independently associated with better treatment outcomes than HA genotypes in the general population [26, 27]. In the early 2000s, 80% of HD patients with MRSA bacteremia were infected with HA.
Table 2. Univariate analyses of the association between potential predictor variables and treatment failure in patients with methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia.

| Variable                                      | Odds Ratio (95% CI) | p value |
|-----------------------------------------------|--------------------|---------|
| Age, per year increase                        | 1.03 (0.99–1.06)   | 0.105   |
| Weight, per kg increase                       | 1.00 (0.97–1.04)   | 0.935   |
| Duration of dialysis, year                    | 0.98 (0.90–1.07)   | 0.696   |
| Duration of dialysis, < 1 year                | 1.69 (0.78–3.65)   | 0.183   |
| NCTC                                          | 0.47 (0.21–1.03)   | 0.060   |
| AVG                                           | 1.57 (0.57–4.36)   | 0.386   |
| AVF                                           | 0.69 (0.27–1.77)   | 0.442   |
| CTC                                           | 3.07 (1.07–8.84)   | 0.038   |
| Diabetes                                      | 1.20 (0.54–2.69)   | 0.652   |
| Congestive heart failure                      | 0.46 (0.18–1.18)   | 0.107   |
| Hypertension                                  | 0.61 (0.28–1.34)   | 0.217   |
| Cardiovascular disease                        | 2.33 (1.01–5.41)   | 0.048   |
| Cancer                                        | 0.58 (0.20–1.72)   | 0.327   |
| Charlson comorbidity score                    | 0.98 (0.79–1.21)   | 0.834   |
| Hospitalization                               | 3.67 (0.96–14.01)  | 0.057   |
| Previous MRSA colonization/infection          | 3.37 (1.10–10.39)  | 0.034   |
| Surgery                                       | 1.97 (0.91–4.28)   | 0.086   |
| Use of percutaneous devices or catheters      | 0.83 (0.38–1.80)   | 0.637   |
| Long-term-care facility residence             | 1.28 (0.58–2.81)   | 0.544   |
| HO-MRSA                                       | 1.80 (0.77–4.22)   | 0.178   |
| Thrombocytopenia                              | 1.99 (0.84–4.74)   | 0.119   |
| Severe sepsis/shock                           | 6.38 (2.51–16.24)  | 0.000   |
| Pitt score, per increase                      | 2.03 (1.43–2.88)   | 0.000   |
| ICU admission                                 | 4.60 (1.97–10.77)  | 0.000   |
| Skin and soft tissue infection                | 1.45 (0.41–5.08)   | 0.560   |
| Catheter-related infection                    | 0.76 (0.52–1.12)   | 0.165   |
| Arteriovenous fistula/graft infection         | 0.69 (0.27–1.77)   | 0.442   |
| Endocarditis                                  | 10.93 (1.32–90.81) | 0.027   |
| Orthopedic infection                          | 1.79 (0.29–11.20)  | 0.532   |
| Other/unknown infection sites                 | 0.86 (0.18–4.06)   | 0.853   |
| Effective empiric antibiotics                 | 0.97 (0.45–2.10)   | 0.938   |
| Definitive effective antibiotics              | 0.20 (0.02–1.86)   | 0.158   |
| Inadequate vancomycin therapy                 | 0.68 (0.23–1.98)   | 0.480   |
| Concomitant use of ß-lactam antibiotics       | 1.83 (0.85–3.97)   | 0.124   |
| Time to remove infected source, days          | 1.05 (0.97–1.15)   | 0.229   |
| Vancomycin MIC\(≥1.5\)                       | 3.53 (1.57–7.94)   | 0.002   |
| CA genotypes                                  | 0.15 (0.06–0.37)   | 0.001   |

AVF, arteriovenous fistula; AVG, arteriovenous graft; CTC, cuffed tunneled catheter; HTN, hypertension; HO, hospital associated hospital onset; MIC, minimal inhibitory concentration; MRSA, methicillin-resistant *staphylococcus aureus*; NCTC, non-cuffed tunneled catheter; TC, tunneled catheter; 95% CI, 95% confidence interval.

https://doi.org/10.1371/journal.pone.0198486.t002

Only a few studies have evaluated the impact of CA or HA genotypes in the HD population. Earlier reports revealed that CA genotypes were not significantly associated with 30-day mortality [28, 29]. In this study, the characteristics of patients with HO-MRSA bacteremia included a shorter duration of HD, more severe clinical presentation,
and more catheter-related/vascular access infections, but this epidemiological classification of MRSA infections (HO- or CO-MRSA) was not associated with treatment failure. Strain differences were observed between HO-MRSA (76% HA genotypes and 24% CA genotypes) and CO-MRSA (38% HA genotypes and 62% CA genotypes). A study in the USA showed that patients who resided in long-term care facilities were less likely to harbor CA genotypes [30], but the current study did not demonstrate the importance of this factor in Taiwan. It has been reported that CA genotypes were more prevalent in patients with a lower number of HA risk factors [31]. However, the numbers of HA risk factors were not significantly different between groups with CA- or HA genotypes in the HD population in this study (p = 0.243). In Taiwan, CA genotypes have circulated in the healthcare setting; traditional distinctions between HA-MRSA and CA-MRSA strains based on clinical characteristics are

| Variable                                      | Univariate analysis | Multivariate analysis |
|-----------------------------------------------|---------------------|-----------------------|
|                                               | Odds Ratio (95% CI) | p value               |
| CTC                                           | 3.07 (1.07–8.84)    | 0.038                 |
| Cardiovascular disease                        | 2.33 (1.01–5.41)    | 0.048                 |
| Previous MRSA colonization/inflection         | 3.37 (1.10–10.39)   | 0.034                 |
| Pitt score, per increase                      | 2.03 (1.43–2.88)    | ...                   |
| Endocarditis                                  | 10.93 (1.32–90.81)  | 0.027                 |
| Vancomycin MIC ≥1.5                          | 3.53 (1.57–7.94)    | 0.002                 |
| CA genotypes                                  | 0.15 (0.06–0.37)    | 0.000                 |
|                                               |                     |                       |
| CTC, cuffed tunneled catheter; MIC, minimal inhibitory concentration; MRSA, methicillin-resistant staphylococcus aureus; NE, not entered into logistic regression model; 95% CI, 95% confidence interval

Table 4. Subgroup analysis of the association between potential predictor variables and treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia.

| Variable                                      | Multivariate analysis for subgroups |
|-----------------------------------------------|------------------------------------|
|                                               | Pitt score ≤ 2 (n = 71) | Pitt score > 2 (n = 35) | CO-MRSA (n = 76) | HO-MRSA (n = 30) |
|                                               | Odds Ratio (95% CI) | p value | Odds Ratio (95% CI) | p value | Odds Ratio (95% CI) | p value | Odds Ratio (95% CI) | p value |
| CTC                                           | ...                   | ...     | ...                   | ...     | ...                   | ...     | ...                   | ...     |
| Cardiovascular disease                        | 3.25 (0.87–12.22)    | 0.081   | ...                   | ...     | ...                   | ...     | ...                   | ...     |
| Previous MRSA colonization/infection          | ...                   | ...     | 13.63 (2.35–79.10)   | 0.004   | 0.06 (0.004–0.81)    | 0.035   | ...                   | ...     |
| Pitt score, per increase                      | NE                   | NE      | 2.86 (1.39–5.90)     | 0.004   | ...                   | ...     | ...                   | ...     |
| Endocarditis                                  | 8.93 (0.73–109.10)   | 0.086   | ...                   | ...     | ...                   | ...     | ...                   | ...     |
| Vancomycin MIC ≥1.5                          | ...                   | ...     | 9.73 (0.65–145.51)   | 0.099   | ...                   | ...     | ...                   | ...     |
| CA genotypes                                  | 0.14 (0.04–0.50)     | 0.002   | 0.20 (0.03–1.19)     | 0.076   | 0.08 (0.02–0.40)     | 0.002   | 0.06 (0.004–0.81)    | 0.035   |

CTC, cuffed tunneled catheter; CO, hospital-associated community onset; HO, hospital-associated hospital onset; MIC, minimal inhibitory concentration; MRSA, methicillin-resistant staphylococcus aureus; NE, not entered into logistic regression model; 95% CI, 95% confidence interval
becoming less useful [6, 7]. Our results support that the approach that differentiated CA- or HA-MRSA strains based on SCC\textit{mec} type is of clinical significance.

We evaluated multiple factors, including patient comorbidities, clinical syndromes, clinical severity and therapeutic strategies, and demonstrated that CA genotypes were significantly associated with better clinical outcomes in the HD population (OR: 0.18; 95% CI, 0.07–0.49; \( p = 0.001 \)). In this study, the vancomycin MICs were lower for CA-MRSA strains than for HA-MRSA strains. In the sub-analysis according to different vancomycin MICs, CA genotypes represented an independent risk factor for clinical outcomes among isolates with vancomycin MICs < 1.5 mg/L (OR: 0.03; 95% CI, 0.003–0.26; \( p = 0.001 \)). The strain-specific differences in clinical outcomes have been suggested to be due to different intrinsic virulence factors [26, 27, 32]. Among isolates with vancomycin MICs ≥ 1.5 mg/L, the only significant factor for clinical outcome was clinical severity (OR: 1.76; 95% CI, 1.02–3.05; \( p = 0.043 \)). The effect of CA genotypes on clinical outcomes was not observed with vancomycin MICs ≥ 1.5 mg/L.

Maintaining a vancomycin trough level within 15–20 mg/L to treat severe MRSA infections is recommended because a ratio of the vancomycin level area under the curve to the minimum inhibitory concentration of the \textit{S. aureus} isolate (AUC/MIC) of > 400 can be targeted [16]. However, inadequate vancomycin therapy was not associated with treatment failure in this study. Because the value of the AUC may be significantly increased in the HD population, aggressively targeting a pre-HD level of 15–20 mg/L may not be needed to achieve an AUC/MIC ratio > 400 [33]. This may be the reason that 12% of the patients with low vancomycin trough levels in this study did not have poor clinical outcomes.

The limitations of this study include the following: first, an information bias may have been introduced due to the nature of the retrospective design. Second, this study was conducted in a single center in Taiwan, and the predominant CA genotypes in this study were ST59-SCC\textit{mec} type IV and ST45-SCC\textit{mec} type V. Whether our study findings can be generalized to different CA genotypes circulating in other HD populations in different geographic regions should be further evaluated.

In conclusion, these findings indicate that CA genotypes, but not the epidemiologic classification of CO-MRSA, impact the clinical outcome of MRSA bacteremia in the HD population. The difference in clinical impact between CA and HA genotypes was significant for isolates with vancomycin MICs < 1.5 mg/L.

### Supporting information

**S1 Table.** Infected source removal rate in different infection foci between healthcare-associated community onset (CO)- and healthcare-associated hospital onset (HO)- methicillin-resistant \textit{Staphylococcus aureus} (MRSA) infections in hemodialysis patients.

(DOCX)

**S2 Table.** Demographic data, clinical features, molecular characteristics and therapeutic characteristics between SCC\textit{mec} type IV or V and SCC\textit{mec} type I, II or III genotypes of methicillin-resistant \textit{Staphylococcus aureus} (MRSA) infections in hemodialysis patients.

(DOCX)

**S3 Table.** Infected source removal rate in different infection foci between SCC\textit{mec} type IV or V and SCC\textit{mec} type I, II or III genotypes of methicillin-resistant \textit{Staphylococcus aureus} (MRSA) infections in hemodialysis patients.

(DOCX)
Acknowledgments

This work was supported by Kaohsiung Medical University Hospital, Taiwan and by a grant from the Center for Infectious Disease and Cancer Research, Kaohsiung Medical University (KMUTP105) and a grant from Kaohsiung Medical University Research Foundation (KMUOR105 and KMUH106-6M16).

Author Contributions

Conceptualization: Shang-Yi Lin, Po-Liang Lu.

Data curation: Shang-Yi Lin, Hung-Pin Tu, Tun-Chieh Chen, Mei-Chiou Shen.

Formal analysis: Shang-Yi Lin, Hung-Pin Tu, Tun-Chieh Chen, Mei-Chiou Shen, Yi-Wen Chiu, Yen-Hsu Chen, Po-Liang Lu.

Funding acquisition: Shang-Yi Lin, Po-Liang Lu.

Investigation: Shang-Yi Lin, Mei-Chiou Shen, Yi-Wen Chiu, Yen-Hsu Chen, Po-Liang Lu.

Methodology: Shang-Yi Lin, Hung-Pin Tu, Mei-Chiou Shen, Yi-Wen Chiu, Yen-Hsu Chen, Po-Liang Lu.

Project administration: Shang-Yi Lin, Po-Liang Lu.

Resources: Tun-Chieh Chen, Mei-Chiou Shen, Yi-Wen Chiu, Po-Liang Lu.

Software: Hung-Pin Tu.

Supervision: Shang-Yi Lin, Hung-Pin Tu, Tun-Chieh Chen, Yi-Wen Chiu, Po-Liang Lu.

Validation: Shang-Yi Lin, Hung-Pin Tu, Tun-Chieh Chen, Mei-Chiou Shen, Yi-Wen Chiu, Yen-Hsu Chen, Po-Liang Lu.

Visualization: Shang-Yi Lin, Yen-Hsu Chen, Po-Liang Lu.

Writing – original draft: Shang-Yi Lin.

Writing – review & editing: Shang-Yi Lin, Hung-Pin Tu, Tun-Chieh Chen, Mei-Chiou Shen, Yi-Wen Chiu, Yen-Hsu Chen, Po-Liang Lu.

References

1. Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA internal medicine. 2013; 173:1970–1978. https://doi.org/10.1001/jamainternmed.2013.10423 PMID: 24043270

2. Langley G, Schaffner W, Farley MM, Lynfield R, Bennett NM, Reingold A, et al. Twenty years of active bacterial core surveillance. Emerg Infect Dis. 2015; 21:1520–1528. https://doi.org/10.3201/eid2109.141333 PMID: 26292067

3. Nguyen DB, Lessa FC, Belflower R, Mu Y, Wise M, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections among patients on chronic dialysis in the United States, 2005–2011. Clin Infect Dis. 2013; 57:1393–1400. https://doi.org/10.1093/cid/cit546 PMID: 23964088

4. Centers for Disease Control and Prevention. Active Bacterial Core surveillance report, Emerging Infections Program Network, Methicillin-resistant Staphylococcus aureus, 2014. https://www.cdc.gov/abcs/reports-findings/survreports/mrsa14.html. Accessed 16 February 2017

5. Nissenson AR, Dylan ML, Griffiths RI, Yu HT, Dean BB, Danese MD, et al. Clinical and economic outcomes of Staphylococcus aureus sepsicemia in ESRD patients receiving hemodialysis. Am J Kidney Dis. 2005; 46:301–308. https://doi.org/10.1053/j.ajkd.2005.04.019 PMID: 16112049

6. Millar BC, Loughrey A, Elborn JS, Moore JE. Proposed definitions of community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA). J Hosp Infect. 2007; 67:109–113. https://doi.org/10.1016/j.jhin.2007.06.003 PMID: 17669546
7. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) A clinician’s guide to community MRSA—its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis. 2011; 52:99–114. https://doi.org/10.1093/cid/ciq067 PMID: 21148528

8. Chuang YY, Huang YC. Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Asia. Lancet Infect Dis. 2013; 13: 698–708. https://doi.org/10.1016/S1473-3099(13)70136-1 PMID: 23827369

9. Talan DA, Krishnadasan A, Gorwitz RJ, Osolinski GE, Limbago B, Albrecht V, et al. Comparison of Staphylococcus aureus from skin and soft tissue infections in adult patients, 2004 and 2008. Clin Infect Dis. 2011; 53:144–149. https://doi.org/10.1093/cid/cir308 PMID: 21690621

10. Holzknecht B, Hardardottir H, Haraldsson G, Westh H, Valsdottir F, Boye K, et al. Changing epidemiology of methicillin-resistant Staphylococcus aureus in Iceland from 2000 to 2008: a challenge to current guidelines. J Clin Microbiol. 2010; 48:4221–4227. https://doi.org/10.1128/JCM.01382-10 PMID: 20864224

11. Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis. 2008; 46:787–794. https://doi.org/10.1086/528716 PMID: 18266611

12. Klevens RM, Morrison MA, Fridkin SK, Reingold A, Petit S, Gershman K, et al. Community-associated methicillin-resistant Staphylococcus aureus and healthcare risk factors. Emerg Infect Dis. 2006; 12:1991–1993. https://doi.org/10.3201/eid1212.060505 PMID: 17326962

13. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): A prospective study. JAMA. 1995; 273:117–123. PMID: 7799491

14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010.

15. Lin SY, Shen MC, Hwang SJ, Chen YH, Chen TC, Chiu YW, et al. Evaluation of vancomycin dosing protocols to achieve therapeutic serum concentrations in patients receiving high-flux hemodialysis. Int J Antimicrob Agents. 2014; 43:384–5. https://doi.org/10.1016/j.ijantimicag.2014.01.002 PMID: 24556550

16. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52:e18–55. https://doi.org/10.1093/cid/ciq146 PMID: 21208910

17. Dilworth TJ, Ibrahim O, Hall P, Slivinski J, Walraven C, Mercier RC. Beta-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother. 2014; 58:102–109. https://doi.org/10.1128/AAC.01204-13 PMID: 24145519

18. Walsh TR, Bolmstrom A, Qwamstrom A, Ho P, Wootten M, Howe RA, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001; 39:2439–2444. https://doi.org/10.1128/JCM.39.7.2439-2444.2001 PMID: 11427551

19. Ernright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol. 2000; 38:1008–1015. PMID: 10698988

20. Lu PL, Chang JC, Hsu HT, Chen JH, Chen FJ, Lin SF, et al. One tube multiplex PCR for simple screening of SCCmec I-V types of methicillin-resistant Staphylococcus aureus. J Chemother. 2008; 20:690–696. https://doi.org/10.1179/joc.2008.20.6.690 PMID: 19129065

21. Gilot P, Lina G, Cochard T, Poutrel B. Analysis of the genetic variability of genes encoding the RNA III-activating components Agr and TRAP in a population of Staphylococcus aureus strains isolated from cows with mastitis. J Clin Microbiol. 2002; 40:4060–4067. https://doi.org/10.1128/JCM.40.11.4060-4067.2002 PMID: 12409375

22. Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis. 2008; 46:787–794. https://doi.org/10.1086/528716 PMID: 18266611

23. Song JH, Hseuh PR, Chung DR, Ko KS, Kang CI, Peck KR, et al. Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother. 2011; 66:1061–1069. https://doi.org/10.1093/jac/dkr024 PMID: 21393157

24. Lee SC, Lee CW, Shih HJ, Chiou MJ, See LC, Siu LK. Clinical features and risk factors of mortality for bacteremia due to community-onset healthcare-associated methicillin-resistant S. aureus. Diagn Microbiol Infect Dis. 2013; 76:86–92. https://doi.org/10.1016/j.diagmicrobio.2013.01.017 PMID: 23420009
25. Tsao FY, Kou HW, Huang YC. Dissemination of methicillin-resistant Staphylococcus aureus sequence type 45 among nursing home residents and staff in Taiwan. Clin Microbiol Infect. 2015; 21:451–458. https://doi.org/10.1016/j.cmi.2014.12.019 PMID: 25677257

26. Chen SY, Liao CH, Wang JL, Chiang WC, Lai MS, Chie WC, et al. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration. Clin Infect Dis. 2012; 55:1329–1337. https://doi.org/10.1093/cid/cis717 PMID: 22911641

27. Hota B, Lyles R, Rim J, Popovich KJ, Rice T, Aroutcheva A, et al. Predictors of clinical virulence in community-onset methicillin-resistant Staphylococcus aureus infections: the importance of USA300 and pneumonia. Clin Infect Dis. 2011; 53:757–765. https://doi.org/10.1093/cid/cis717 PMID: 21880583

28. Lin CC, Wang JL, Lin CY, Chen SY, Wang JT, Wu KD, et al. Methicillin-resistant Staphylococcus aureus bacteremia in patients with end-stage renal disease in Taiwan: distinguishing between community-associated and healthcare-associated strains. Infect Control Hosp Epidemiol. 2009; 30:89–92. https://doi.org/10.1086/593122 PMID: 19046055

29. Wu HS, Kuo SC, Chen LY, Chiang MC, Lin YT, Wang FD, et al. Comparison between patients under hemodialysis with community-onset bacteremia caused by community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus strains. J Microbiol Immunol Infect. 2013; 46:96–103. https://doi.org/10.1016/j.jmii.2012.02.004 PMID: 22520272

30. Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF, King MD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated bloodstream infections. Clin Infect Dis. 2006; 42:647–656. https://doi.org/10.1086/499815 PMID: 16447110

31. Park SH, Park C, Yoo JH, Choi SM, Choi JH, Shin HH, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated bloodstream infections in Korea. Infect Control Hosp Epidemiol. 2009; 30:146–155. https://doi.org/10.1086/593953 PMID: 19128184

32. McNicholas S, Shore AC, Coleman DC, Humphreys H, Hughes DF. DNA microarray genotyping and virulence and antimicrobial resistance gene profiling of methicillin-resistant Staphylococcus aureus bloodstream isolates from renal patients. J Clin Microbiol. 2011; 49:4349–4351. https://doi.org/10.1128/JCM.05017-11 PMID: 21940465

33. Brown M, Polisetty R, Gracely EJ, Cuhaci B, Schlecht HP. Weight-based loading of vancomycin in patients on hemodialysis. Clin Infect Dis. 2011; 53:164–166. https://doi.org/10.1093/cid/cir322 PMID: 21690623